Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 180 entries
Sorted by: Best Match Show Resources per page
The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics.

Multiple sclerosis and related disorders

Lindsey JW, Scott TF, Lynch SG, Cofield SS, Nelson F, Conwit R, Gustafson T, Cutter GR, Wolinsky JS, Lublin FD.
PMID: 25876935
Mult Scler Relat Disord. 2012 Apr;1(2):81-6. doi: 10.1016/j.msard.2012.01.006. Epub 2012 Feb 23.

BACKGROUND: Interferon-β1a (IFNB) and glatiramer acetate (GA) are distinct therapies which are both partially effective for relapsing MS. It is not known if combining the two treatments would be more effective.OBJECTIVE: To review the rationale, design, and baseline characteristics...

Cite
Lindsey JW, Scott TF, Lynch SG, et al. The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics. Mult Scler Relat Disord. 2012;1(2):81-6doi: 10.1016/j.msard.2012.01.006.
Lindsey, J. W., Scott, T. F., Lynch, S. G., Cofield, S. S., Nelson, F., Conwit, R., Gustafson, T., Cutter, G. R., Wolinsky, J. S., Lublin, F. D. (2012). The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics. Multiple sclerosis and related disorders, 1(2), 81-6. https://doi.org/10.1016/j.msard.2012.01.006
Lindsey, J W, et al. "The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics." Multiple sclerosis and related disorders vol. 1,2 (2012): 81-6. doi: https://doi.org/10.1016/j.msard.2012.01.006
Lindsey JW, Scott TF, Lynch SG, Cofield SS, Nelson F, Conwit R, Gustafson T, Cutter GR, Wolinsky JS, Lublin FD. The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics. Mult Scler Relat Disord. 2012 Apr;1(2):81-6. doi: 10.1016/j.msard.2012.01.006. Epub 2012 Feb 23. PMID: 25876935.
Copy Download .nbib Format: NLM
Interferon beta-1a-induced morphea.

JAAD case reports

Bezalel SA, Strober BE, Ferenczi K.
PMID: 27075128
JAAD Case Rep. 2014 Oct 05;1(1):15-7. doi: 10.1016/j.jdcr.2014.10.002. eCollection 2015 Jan.

No abstract available.

Cite
Bezalel SA, Strober BE, Ferenczi K. Interferon beta-1a-induced morphea. JAAD Case Rep. 2014;1(1):15-7doi: 10.1016/j.jdcr.2014.10.002.
Bezalel, S. A., Strober, B. E., & Ferenczi, K. (2015). Interferon beta-1a-induced morphea. JAAD case reports, 1(1), 15-7. https://doi.org/10.1016/j.jdcr.2014.10.002
Bezalel, Spencer A, et al. "Interferon beta-1a-induced morphea." JAAD case reports vol. 1,1 (2015): 15-7. doi: https://doi.org/10.1016/j.jdcr.2014.10.002
Bezalel SA, Strober BE, Ferenczi K. Interferon beta-1a-induced morphea. JAAD Case Rep. 2014 Oct 05;1(1):15-7. doi: 10.1016/j.jdcr.2014.10.002. eCollection 2015 Jan. PMID: 27075128; PMCID: PMC4802549.
Copy Download .nbib Format: NLM
Financial and Clinical Implications of Intramuscular Versus Subcutaneous Interferon Beta-1a in Portugal, Based on the Findings from the Cochrane Collaboration Review of First-Line Treatments for Relapsing-Remitting Multiple Sclerosis.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Silverio N, Sequeira L, Meletiche D.
PMID: 27200931
Value Health. 2014 Nov;17(7):A396. doi: 10.1016/j.jval.2014.08.887. Epub 2014 Oct 26.

No abstract available.

Cite
Silverio N, Sequeira L, Meletiche D. Financial and Clinical Implications of Intramuscular Versus Subcutaneous Interferon Beta-1a in Portugal, Based on the Findings from the Cochrane Collaboration Review of First-Line Treatments for Relapsing-Remitting Multiple Sclerosis. Value Health. 2014;17(7):A396doi: 10.1016/j.jval.2014.08.887.
Silverio, N., Sequeira, L., & Meletiche, D. (2014). Financial and Clinical Implications of Intramuscular Versus Subcutaneous Interferon Beta-1a in Portugal, Based on the Findings from the Cochrane Collaboration Review of First-Line Treatments for Relapsing-Remitting Multiple Sclerosis. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A396. https://doi.org/10.1016/j.jval.2014.08.887
Silverio, N, et al. "Financial and Clinical Implications of Intramuscular Versus Subcutaneous Interferon Beta-1a in Portugal, Based on the Findings from the Cochrane Collaboration Review of First-Line Treatments for Relapsing-Remitting Multiple Sclerosis." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A396. doi: https://doi.org/10.1016/j.jval.2014.08.887
Silverio N, Sequeira L, Meletiche D. Financial and Clinical Implications of Intramuscular Versus Subcutaneous Interferon Beta-1a in Portugal, Based on the Findings from the Cochrane Collaboration Review of First-Line Treatments for Relapsing-Remitting Multiple Sclerosis. Value Health. 2014 Nov;17(7):A396. doi: 10.1016/j.jval.2014.08.887. Epub 2014 Oct 26. PMID: 27200931.
Copy Download .nbib Format: NLM
Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis.

Therapeutics and clinical risk management

Cocco E, Marrosu MG.
PMID: 26056458
Ther Clin Risk Manag. 2015 May 08;11:759-66. doi: 10.2147/TCRM.S69123. eCollection 2015.

Several treatments are currently available for relapsing-remitting multiple sclerosis. Among them, interferon (IFN) beta remains a valid treatment approach because of its good benefit/risk profile. Due to the need for frequent administration (weekly, at a minimum), the use of...

Cite
Cocco E, Marrosu MG. Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis. Ther Clin Risk Manag. 2015;11:759-66doi: 10.2147/TCRM.S69123.
Cocco, E., & Marrosu, M. G. (2015). Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis. Therapeutics and clinical risk management, 11759-66. https://doi.org/10.2147/TCRM.S69123
Cocco, Eleonora, and Marrosu, Maria Giovanna. "Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis." Therapeutics and clinical risk management vol. 11 (2015): 759-66. doi: https://doi.org/10.2147/TCRM.S69123
Cocco E, Marrosu MG. Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis. Ther Clin Risk Manag. 2015 May 08;11:759-66. doi: 10.2147/TCRM.S69123. eCollection 2015. PMID: 26056458; PMCID: PMC4431469.
Copy Download .nbib Format: NLM
Appropriate use of interferon beta-1a in multiple sclerosis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Jacobs L, Brownscheidle CM.
PMID: 18031126
BioDrugs. 1999 Mar;11(3):155-63. doi: 10.2165/00063030-199911030-00002.

Multiple sclerosis (MS), a chronic inflammatory demyelinating disease of the central nervous system, is the most common crippling neurological disease of young adults in the US. The 2 basic clinical forms of the disease (relapsing and progressive), which can...

Cite
Jacobs L, Brownscheidle CM. Appropriate use of interferon beta-1a in multiple sclerosis. BioDrugs. 1999;11(3):155-63doi: 10.2165/00063030-199911030-00002.
Jacobs, L., & Brownscheidle, C. M. (1999). Appropriate use of interferon beta-1a in multiple sclerosis. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 11(3), 155-63. https://doi.org/10.2165/00063030-199911030-00002
Jacobs, L, and Brownscheidle, C M. "Appropriate use of interferon beta-1a in multiple sclerosis." BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 11,3 (1999): 155-63. doi: https://doi.org/10.2165/00063030-199911030-00002
Jacobs L, Brownscheidle CM. Appropriate use of interferon beta-1a in multiple sclerosis. BioDrugs. 1999 Mar;11(3):155-63. doi: 10.2165/00063030-199911030-00002. PMID: 18031126.
Copy Download .nbib Format: NLM
Dose and Frequency of Administration of Interferon-beta Affect its Efficacy in Multiple Sclerosis.

Clinical drug investigation

Sharief MK.
PMID: 17535068
Clin Drug Investig. 2003;23(9):551-9. doi: 10.2165/00044011-200323090-00001.

Data reviewed in this article demonstrate that both interferon-beta-1a (IFNbeta-1a) and interferon-beta-1b (IFNbeta-1b) show a dose-response relationship in multiple sclerosis at current clinical doses. Moreover, the efficacy of these therapies is probably dependent on their frequent administration to maintain...

Cite
Sharief MK. Dose and Frequency of Administration of Interferon-beta Affect its Efficacy in Multiple Sclerosis. Clin Drug Investig. 2003;23(9):551-9doi: 10.2165/00044011-200323090-00001.
Sharief, M. K. (2003). Dose and Frequency of Administration of Interferon-beta Affect its Efficacy in Multiple Sclerosis. Clinical drug investigation, 23(9), 551-9. https://doi.org/10.2165/00044011-200323090-00001
Sharief, Mohammed K. "Dose and Frequency of Administration of Interferon-beta Affect its Efficacy in Multiple Sclerosis." Clinical drug investigation vol. 23,9 (2003): 551-9. doi: https://doi.org/10.2165/00044011-200323090-00001
Sharief MK. Dose and Frequency of Administration of Interferon-beta Affect its Efficacy in Multiple Sclerosis. Clin Drug Investig. 2003;23(9):551-9. doi: 10.2165/00044011-200323090-00001. PMID: 17535068.
Copy Download .nbib Format: NLM
Alemtuzumab versus interferon beta-1a in early multiple sclerosis.

Current neurology and neuroscience reports

Bourdette D, Yadav V.
PMID: 19664362
Curr Neurol Neurosci Rep. 2009 Sep;9(5):341-2. doi: 10.1007/s11910-009-0062-1.

No abstract available.

Cite
Bourdette D, Yadav V. Alemtuzumab versus interferon beta-1a in early multiple sclerosis. Curr Neurol Neurosci Rep. 2009;9(5):341-2doi: 10.1007/s11910-009-0062-1.
Bourdette, D., & Yadav, V. (2009). Alemtuzumab versus interferon beta-1a in early multiple sclerosis. Current neurology and neuroscience reports, 9(5), 341-2. https://doi.org/10.1007/s11910-009-0062-1
Bourdette, Dennis, and Yadav, Vijayshree. "Alemtuzumab versus interferon beta-1a in early multiple sclerosis." Current neurology and neuroscience reports vol. 9,5 (2009): 341-2. doi: https://doi.org/10.1007/s11910-009-0062-1
Bourdette D, Yadav V. Alemtuzumab versus interferon beta-1a in early multiple sclerosis. Curr Neurol Neurosci Rep. 2009 Sep;9(5):341-2. doi: 10.1007/s11910-009-0062-1. PMID: 19664362.
Copy Download .nbib Format: NLM
Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study.

Patient preference and adherence

Camu W, Hadjout K, Latour S, Pöhlau D, Masri S.
PMID: 20517473
Patient Prefer Adherence. 2010 May 13;4:127-33. doi: 10.2147/ppa.s10468.

OBJECTIVE: To assess satisfaction with the serum-free formulation of subcutaneous (sc) interferon (IFN) beta-1a among patients with relapsing multiple sclerosis (MS).METHODS: Patients with relapsing MS who had been receiving sc IFN beta-1a for at least 6 months, were transitioned...

Cite
Camu W, Hadjout K, Latour S, et al. Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study. Patient Prefer Adherence. 2010;4:127-33doi: 10.2147/ppa.s10468.
Camu, W., Hadjout, K., Latour, S., Pöhlau, D., & Masri, S. (2010). Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study. Patient preference and adherence, 4127-33. https://doi.org/10.2147/ppa.s10468
Camu, William, et al. "Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study." Patient preference and adherence vol. 4 (2010): 127-33. doi: https://doi.org/10.2147/ppa.s10468
Camu W, Hadjout K, Latour S, Pöhlau D, Masri S. Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study. Patient Prefer Adherence. 2010 May 13;4:127-33. doi: 10.2147/ppa.s10468. PMID: 20517473; PMCID: PMC2875722.
Copy Download .nbib Format: NLM
Oral fingolimod for relapsing-remitting multiple sclerosis Evaluation of: Kappos L, Radue E-M, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401; and Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15.

Expert opinion on pharmacotherapy

Doggrell SA.
PMID: 20408749
Expert Opin Pharmacother. 2010 Jul;11(10):1777-81. doi: 10.1517/14656566.2010.481671.

Most people with multiple sclerosis (MS) have the relapsing-remitting type. The objective was to evaluate two clinical trials of fingolimod in relapsing MS. FREEDOMS (FTY720 Research Evaluation Effects of Daily Oral therapy in Multiple Sclerosis), a Phase III placebo-controlled...

Cite
Doggrell SA. Oral fingolimod for relapsing-remitting multiple sclerosis Evaluation of: Kappos L, Radue E-M, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401; and Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15. Expert Opin Pharmacother. 2010;11(10):1777-81doi: 10.1517/14656566.2010.481671.
Doggrell, S. A. (2010). Oral fingolimod for relapsing-remitting multiple sclerosis Evaluation of: Kappos L, Radue E-M, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401; and Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15. Expert opinion on pharmacotherapy, 11(10), 1777-81. https://doi.org/10.1517/14656566.2010.481671
Doggrell, Sheila A. "Oral fingolimod for relapsing-remitting multiple sclerosis Evaluation of: Kappos L, Radue E-M, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401; and Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15." Expert opinion on pharmacotherapy vol. 11,10 (2010): 1777-81. doi: https://doi.org/10.1517/14656566.2010.481671
Doggrell SA. Oral fingolimod for relapsing-remitting multiple sclerosis Evaluation of: Kappos L, Radue E-M, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401; and Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15. Expert Opin Pharmacother. 2010 Jul;11(10):1777-81. doi: 10.1517/14656566.2010.481671. PMID: 20408749.
Copy Download .nbib Format: NLM
Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN.

Therapeutic advances in neurological disorders

Newsome SD, Scott TF, Arnold DL, Nelles G, Hung S, Cui Y, Shang S, Naylor ML, Kremenchutzky M.
PMID: 30181778
Ther Adv Neurol Disord. 2018 Aug 28;11:1756286418791143. doi: 10.1177/1756286418791143. eCollection 2018.

BACKGROUND: ADVANCE was a phase III trial of the efficacy and safety of subcutaneous peginterferon beta-1a 125 µg every 2 or 4 weeks in patients with relapsing-remitting multiple sclerosis (RRMS). ATTAIN was a 2-year extension study of ADVANCE. The...

Cite
Newsome SD, Scott TF, Arnold DL, et al. Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN. Ther Adv Neurol Disord. 2018;11:1756286418791143doi: 10.1177/1756286418791143.
Newsome, S. D., Scott, T. F., Arnold, D. L., Nelles, G., Hung, S., Cui, Y., Shang, S., Naylor, M. L., & Kremenchutzky, M. (2018). Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN. Therapeutic advances in neurological disorders, 111756286418791143. https://doi.org/10.1177/1756286418791143
Newsome, Scott D, et al. "Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN." Therapeutic advances in neurological disorders vol. 11 (2018): 1756286418791143. doi: https://doi.org/10.1177/1756286418791143
Newsome SD, Scott TF, Arnold DL, Nelles G, Hung S, Cui Y, Shang S, Naylor ML, Kremenchutzky M. Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN. Ther Adv Neurol Disord. 2018 Aug 28;11:1756286418791143. doi: 10.1177/1756286418791143. eCollection 2018. PMID: 30181778; PMCID: PMC6113734.
Copy Download .nbib Format: NLM
Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study.

Therapeutic advances in neurological disorders

Kallmann BA, Tiel-Wilck K, Kullmann JS, Engelmann U, Chan A.
PMID: 30944584
Ther Adv Neurol Disord. 2019 Mar 27;12:1756286419835077. doi: 10.1177/1756286419835077. eCollection 2019.

BACKGROUND: Teriflunomide is a once-daily oral immunomodulatory agent approved for the treatment of relapsing-remitting multiple sclerosis (MS). We aimed to obtain data on the effectiveness, tolerability, and subject satisfaction with teriflunomide (Aubagio®) under clinical practice conditions in unselected MS...

Cite
Kallmann BA, Tiel-Wilck K, Kullmann JS, et al. Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study. Ther Adv Neurol Disord. 2019;12:1756286419835077doi: 10.1177/1756286419835077.
Kallmann, B. A., Tiel-Wilck, K., Kullmann, J. S., Engelmann, U., & Chan, A. (2019). Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study. Therapeutic advances in neurological disorders, 121756286419835077. https://doi.org/10.1177/1756286419835077
Kallmann, Boris A, et al. "Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study." Therapeutic advances in neurological disorders vol. 12 (2019): 1756286419835077. doi: https://doi.org/10.1177/1756286419835077
Kallmann BA, Tiel-Wilck K, Kullmann JS, Engelmann U, Chan A. Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study. Ther Adv Neurol Disord. 2019 Mar 27;12:1756286419835077. doi: 10.1177/1756286419835077. eCollection 2019. PMID: 30944584; PMCID: PMC6437319.
Copy Download .nbib Format: NLM
Idiopathic Thrombocytopenic Purpura: A Rare Syndrome with Alemtuzumab, Review of Monitoring Protocol.

Cureus

Sarvepalli D, Rashid MU, Ullah W, Zafar Y, Khan M.
PMID: 31720183
Cureus. 2019 Sep 20;11(9):e5715. doi: 10.7759/cureus.5715.

Alemtuzumab, a humanized monoclonal antibody that targets surface molecule CD52, causes rapid and complete depletion of circulating T- and B-lymphocytes through antibody-dependent cell-mediated and complement-mediated cytotoxicity. Alemtuzumab has demonstrated superior efficacy compared to subcutaneous interferon beta-1a (SC IFNB-1a) in...

Cite
Sarvepalli D, Rashid MU, Ullah W, et al. Idiopathic Thrombocytopenic Purpura: A Rare Syndrome with Alemtuzumab, Review of Monitoring Protocol. Cureus. 2019;11(9):e5715doi: 10.7759/cureus.5715.
Sarvepalli, D., Rashid, M. U., Ullah, W., Zafar, Y., & Khan, M. (2019). Idiopathic Thrombocytopenic Purpura: A Rare Syndrome with Alemtuzumab, Review of Monitoring Protocol. Cureus, 11(9), e5715. https://doi.org/10.7759/cureus.5715
Sarvepalli, Deepika, et al. "Idiopathic Thrombocytopenic Purpura: A Rare Syndrome with Alemtuzumab, Review of Monitoring Protocol." Cureus vol. 11,9 (2019): e5715. doi: https://doi.org/10.7759/cureus.5715
Sarvepalli D, Rashid MU, Ullah W, Zafar Y, Khan M. Idiopathic Thrombocytopenic Purpura: A Rare Syndrome with Alemtuzumab, Review of Monitoring Protocol. Cureus. 2019 Sep 20;11(9):e5715. doi: 10.7759/cureus.5715. PMID: 31720183; PMCID: PMC6823085.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 180 entries